T Amorim-Barbosa1, M P Serrão2, I Brandão3, M A Vieira-Coelho2,4. 1. Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Alameda Prof. Hernâni Monteiro, 4200-319, Porto, Portugal. tiagomab2@gmail.com. 2. Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Alameda Prof. Hernâni Monteiro, 4200-319, Porto, Portugal. 3. Psychiatry and Mental Health Clinic, São João Hospital-Medical Centre, Porto, Portugal. 4. Center for Drug Discovery and Innovative Medicines (MedInUP), University of Porto, Porto, Portugal.
Abstract
PURPOSE: Abnormal feeding has been linked to disruptions in brain dopaminergic activity and recent studies have assessed the role of catechol-O-methyltransferase (COMT) in eating disorders. This is the first study to quantify the soluble catechol-O-methyltransferase (S-COMT) activity in erythrocytes from patients with anorexia nervosa (AN), bulimia nervosa (BN) and binge-eating disorder (BED) and the first study at all to evaluate the COMT on patients with BED. METHODS: Forty blood samples from patients with AN, BN and BED and healthy controls were drawn to evaluate S-COMT activity in erythrocytes by high-performance liquid chromatography and mass spectrometry. Since several patients were being treated with fluoxetine 20 mg, they were included in a different group (BN MED and BED MED). Liver homogenates from rats were used to evaluate baseline S-COMT activity in the presence of fluoxetine by the same in vitro procedures and assays. RESULTS: Erythrocyte S-COMT activity (pmol/mg prt/h) was significantly increased in patients with BN and BED (41.3 ± 6.8 and 41.4 ± 14, respectively) compared to control group (25.3 ± 9.7). In fluoxetine-treated patients with BN, S-COMT activity (15.9 ± 8.8) was decreased compared to the other BN group; however, in BED group, the difference between BED MED and BED was not observed. In patients with AN, no significant difference was found compared to controls. CONCLUSION: Patients with BN and BED presented higher S-COMT activity in erythrocytes, which is in agreement with previous studies on the literature addressing the high-activity COMT allele, Val158, as risk factor for eating disorders. Although in fluoxetine-treated patients with BN the activity of S-COMT was similar to the controls, this is not explained by a direct interaction between fluoxetine and S-COMT as verified in in vitro assays.
PURPOSE: Abnormal feeding has been linked to disruptions in brain dopaminergic activity and recent studies have assessed the role of catechol-O-methyltransferase (COMT) in eating disorders. This is the first study to quantify the soluble catechol-O-methyltransferase (S-COMT) activity in erythrocytes from patients with anorexia nervosa (AN), bulimia nervosa (BN) and binge-eating disorder (BED) and the first study at all to evaluate the COMT on patients with BED. METHODS: Forty blood samples from patients with AN, BN and BED and healthy controls were drawn to evaluate S-COMT activity in erythrocytes by high-performance liquid chromatography and mass spectrometry. Since several patients were being treated with fluoxetine 20 mg, they were included in a different group (BN MED and BED MED). Liver homogenates from rats were used to evaluate baseline S-COMT activity in the presence of fluoxetine by the same in vitro procedures and assays. RESULTS: Erythrocyte S-COMT activity (pmol/mg prt/h) was significantly increased in patients with BN and BED (41.3 ± 6.8 and 41.4 ± 14, respectively) compared to control group (25.3 ± 9.7). In fluoxetine-treated patients with BN, S-COMT activity (15.9 ± 8.8) was decreased compared to the other BN group; however, in BED group, the difference between BED MED and BED was not observed. In patients with AN, no significant difference was found compared to controls. CONCLUSION:Patients with BN and BED presented higher S-COMT activity in erythrocytes, which is in agreement with previous studies on the literature addressing the high-activity COMT allele, Val158, as risk factor for eating disorders. Although in fluoxetine-treated patients with BN the activity of S-COMT was similar to the controls, this is not explained by a direct interaction between fluoxetine and S-COMT as verified in in vitro assays.
Authors: L L Gorman; M W O'Hara; B Figueiredo; S Hayes; F Jacquemain; M H Kammerer; C M Klier; S Rosi; G Seneviratne; A-L Sutter-Dallay Journal: Br J Psychiatry Suppl Date: 2004-02
Authors: A Frisch; N Laufer; Y Danziger; E Michaelovsky; S Leor; C Carel; D Stein; S Fenig; M Mimouni; A Apter; A Weizman Journal: Mol Psychiatry Date: 2001-03 Impact factor: 15.992
Authors: M Gabrovsek; M Brecelj-Anderluh; L Bellodi; E Cellini; D Di Bella; X Estivill; F Fernandez-Aranda; B Freeman; F Geller; M Gratacos; R Haigh; J Hebebrand; A Hinney; J Holliday; X Hu; A Karwautz; B Nacmias; M Ribases; H Remschmidt; R Komel; S Sorbi; M Tomori; J Treasure; G Wagner; J Zhao; D A Collier Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2004-01-01 Impact factor: 3.568
Authors: Jacinto Nuno da Costa Azevedo; Cláudia Carvalho; Maria Paula Serrão; Rui Coelho; Margarida Figueiredo-Braga; Maria Augusta Vieira-Coelho Journal: BMC Psychiatry Date: 2022-06-21 Impact factor: 4.144